| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Aurinia Pharmaceuticals Inc$15.78
-0.71 (-4.29%)
C 52Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.98 B
EPS
2.26
P/E Ratio
7.11 $
Value Trade
26.62 M
SEC Financials
Q1 2026Dilution Risk
Revenue
77.70 M
R&D Expenses
7.47 M
Operating CF
32.56 M
Total Assets
724.00 M
Total Liabilities
156.37 M
Equity
567.63 M
D/E Ratio
12,345
-2.19 %
Week
-4.46 %
1 Month
5.77 %
3 Month
0.66 %
6 Month
15.92 %
5 Year
642.44 %
All Time
Cash Data
Cash Position
41.01 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
1.20 M
52 Week Range
7.29 - 16.88
% held by Insiders
12.11 %
% held by Institutions
61.76 %
Enterprise Value
1.67 B
Total Shares
129.99 M
Short %
9.31 %
Float Shares
102.95 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aurinia Pharmaceuticals Inc
468Total events
2Upcoming
122Tier-1 (high impact)
2013 – 2031Coverage
Upcoming catalysts 2
Event history 466
Jul 6, 2026
▲Trial InitiationLUPKYNISApprovedTrial
Initiation of PRESERVE study investigating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab
lupus nephritissource ↗
Mar 2026
▲Quarterly UpdateCorporate
Q1 2026 financial results: total revenue $77.7M, net product sales $73.6M, net income $34.4M
Mar 30, 2026
Mar 30, 2026
▲Type C MeetingzetomipzomibFDA Meeting
Positive FDA Type C meeting to accelerate zetomipzomib development in AIH
autoimmune hepatitissource ↗
Feb 26, 2026
Feb 26, 2026
▲Trial InitiationAritinerceptTrial
Initiated clinical study of aritinercept in one autoimmune disease
autoimmune diseasesource ↗
2026
●Quarterly UpdateCorporate
Reiterated 2026 total revenue guidance of $315M-$325M and net product sales guidance of $305M-$315M
Q1 2026
◆Trial InitiationAritinerceptTrial
Plan to initiate clinical study in an additional autoimmune disease in first half of 2026
autoimmune diseasesource ↗
2025
●Trial InitiationAritinerceptTrial
Initiation of clinical studies for aritinercept in two autoimmune diseases
autoimmune diseasessource ↗
Drug Pipeline Intelligence
C52
Pipeline Score $1.6B
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored0.8x
rNPV / MCap Top 79%
Micro Cap (rank 192 of 911)
Percentile RankAurinia Pharmaceuticals Inc carries a moderate pipeline score (52/100), with $4.1B risk-adjusted pipeline value, led by voclosporin in Psoriasis (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| voclosporin Small molecule | Lupus Nephritis | Phase 3 | NCT02949973 | 58% | $3.8B | COMPLETED | 849 | - | - | Feb 17, 2017 | - | Mar 19, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
aritinercept | autoimmune diseases | Phase 1 | 2025-06-30 | immunoglobulin A reduction: up to 48%; immunoglobulin M reduction: 55%; immunoglobulin G reduction: 20% Read More | Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly Read More | |
aritinercept | autoimmune diseases | Phase 1 | 2025-06-30 | immunoglobulin A reduction: up to 48%; immunoglobulin M reduction: 55%; immunoglobulin G reduction: 20% Read More | Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly Read More | |
aritinercept | autoimmune diseases | Phase 1 | 2025-06-30 | immunoglobulin A reduction: up to 48%; immunoglobulin M reduction: 55%; immunoglobulin G reduction: 20% Read More | Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AUPH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AUPH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AUPHAurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Pharmaceuticals has announced the initiation of the PRESERVE study. This clinical trial will investigate the combination of LUPKYNIS with Belimumab, Obinutuzumab, or Anifrolumab in patients suffering from lupus nephritis. The study aims to assess the efficacy of these combinations in treating this condition.
Read more →AUPH▼ -6.8%on this news
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended
Aurinia Pharmaceuticals reported a total revenue of $77.7 million for the three months ended March 31, 2026, a 24% increase from the same period in 2025. The net product sales for LUPKYNIS were $73.6 million, representing a 23% growth. The company also reported a net income of $34.4 million, a 48% increase year-over-year. Additionally, Aurinia reiterated its 2026 guidance, projecting total revenue between $315 million and $325 million.
Read more →AUPHAurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right ROCKVILLE, Maryland and EDMONTON, Alberta, and South San Francisco, California
Aurinia Pharmaceuticals has entered into a definitive agreement to acquire Kezar Life Sciences for $6.955 per share, alongside contingencies related to ongoing development projects. This merger, beneficial for both companies, aims to leverage Aurinia's expertise in autoimmune therapies and Kezar's promising drug, zetomipzomib. The transaction is expected to close in the second quarter of 2026, subject to various conditions. Notably, the deal includes a contingent value right for shareholders of Kezar, enhancing potential financial benefits.
Read more →AUPHAurinia Announces Management Transition ROCKVILLE, Maryland and
Aurinia Pharmaceuticals has announced a management transition where Kevin Tang will take over as CEO from Peter Greenleaf, who will remain as a consultant. The company expresses gratitude for Greenleaf's contributions during his seven-year tenure. Aurinia maintains a strong position in the biopharmaceutical market, highlighted by the success of its drug LUPKYNIS for lupus nephritis and the ongoing development of aritinercept. A new management team has been appointed to support the company's future direction in delivering treatments for autoimmune diseases.
Read more →AUPHAurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals reported financial results for the year ending December 31, 2025, highlighting a cash position of $398 million and a significant increase in LUPKYNIS sales. The company anticipates total revenue between $315 million and $325 million for 2026, reflecting an 11% to 15% increase. Aurinia is also advancing its dual inhibitor, aritinercept, with plans for clinical studies in autoimmune diseases.
Read more →AUPH▲ +8.4%on this news
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended
Aurinia Pharmaceuticals Inc. has reported robust financial results for Q3 and the first nine months of 2025, showcasing a marked growth in LUPKYNIS sales by 27%. The company raised its revenue guidance to between $275 million to $280 million for the full year. Notably, net income saw a staggering increase, with a net profit margin improvement across both reporting periods. Additionally, positive progress was noted in clinical trials for their new drug aritinercept aimed at treating autoimmune diseases.
Read more →AUPHAurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended
Aurinia Pharmaceuticals Inc. reported strong financial results for the second quarter and first half of 2025, with total revenues of $70 million and $132.5 million, representing significant year-over-year growth. Net product sales for its drug LUPKYNIS also increased, reaching $66.6 million and $126.5 million. The company announced an increase in its revenue guidance for the full year 2025, reflecting optimism about future sales. In addition, positive results from a Phase 1 trial of aritinercept were highlighted, suggesting potential advancements in their product pipeline.
Read more →AUPHAurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly
Aurinia Pharmaceuticals announced positive results from a Phase 1 study of aritinercept (AUR200), a dual inhibitor targeting B cell-activating factor and a proliferation-inducing ligand. The drug demonstrated robust and sustainable reductions in immunoglobulins, indicating potential efficacy. Aritinercept was well tolerated at all tested dose levels, with minimal adverse events reported. The company plans to initiate further clinical studies for autoimmune diseases in the latter half of the year.
Read more →AUPH▼ -5%on this news
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended
Aurinia Pharmaceuticals reported a strong financial performance for both the fourth quarter and full year ending December 31, 2024. Revenue for Q4 rose 33% to $59.9 million, driven largely by a 36% increase in net product sales of LUPKYNIS, which reached $57.6 million. The company also reported a net income of $1.4 million for Q4, a remarkable recovery from a loss of $(26.9) million in the prior year. Looking ahead, Aurinia expects 2025 total revenue to range between $250 million and $260 million, reflecting optimistic growth prospects.
Read more →AUPH▲ +10.9%on this news
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development Achieved $67.8
Aurinia Pharmaceuticals has reported strong financial results for the third quarter of 2024, achieving $67.8 million in total net revenue, reflecting a 24% year-over-year growth. The company announced a strategic restructuring plan aimed at streamlining operations, focusing on enhancing the LUPKYNIS franchise, and accelerating the development of AUR200. While the restructuring is expected to result in significant operational cost savings, it will also involve a substantial workforce reduction. Overall, Aurinia maintains a positive outlook, reiterating its revenue guidance for the year.
Read more →AUPHAurinia Announces Board Restructuring Peter Greenleaf, President and Chief Executive Officer of Aurinia, remains a Director Kevin Tang, President of Tang Capital Management, LLC, appointed as a Director The Board has acc
Aurinia Pharmaceuticals Inc. has announced a restructuring of its Board of Directors to better align with shareholder interests. Peter Greenleaf continues as a director, despite a conditional resignation, due to the board's determination of exceptional circumstances. Kevin Tang has been appointed to the board, bringing over 20 years of experience in the biopharmaceutical industry. Additionally, three directors have submitted their conditional resignations following a lack of majority support at the recent Annual General Meeting.
Read more →AUPHAURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2024 FINANCIAL AND OPERATIONAL RESULTS Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of
Aurinia Pharmaceuticals reported its financial results for the second quarter of 2024, showcasing a total net revenue of $57.2 million, a 38% increase from the previous year. The company also generated $15.8 million in free cash flow, enhancing its financial stability. Aurinia is moving forward with its development of AUR200, a new treatment targeting autoimmune diseases, and is anticipating approval for LUPKYNIS in Japan later this year. The company has adjusted its net product revenue guidance to between $210 and $220 million for 2024.
Read more →AUPH▼ -24.5%on this news
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value Total net revenue was $45.1 million and $175.5 million, and net product revenue was $4
Aurinia Pharmaceuticals reported significant financial results for 2023, with total net revenue of $175.5 million, reflecting a 31% year-over-year increase. The company confirmed a net product revenue guidance of $200 - $220 million for 2024. As part of their updated strategy, Aurinia will discontinue its AUR200 and AUR300 programs, leading to a one-time charge of $11 - $15 million but anticipates annual operational cost savings of $50 - $55 million. Additionally, the company announced a share repurchase program of up to $150 million, signaling confidence in its growth prospects.
Read more →AUPH▲ +10.5%on this news
AURINIA PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS Net product revenue of $40.8 million for the third quarter of 2023 an increase of 60% over the prior year third quarter
Aurinia Pharmaceuticals reported robust financial results for Q3 2023, with net product revenue reaching $40.8 million, marking a 60% increase compared to Q3 2022. The total net revenue for the nine months ended September 30, 2023, also increased by 24% year-over-year. The company secured a $10 million milestone from Otsuka Pharmaceutical due to pricing approvals in major European markets and has narrowed its revenue guidance for 2023. Despite some decreases in total net revenue and collaboration revenues, Aurinia continues to show growth in the market for its lupus nephritis treatment, LUPKYNIS.
Read more →AUPHAURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS Net revenue increased to $41.5 million for second quarter of 2023 47% over the prior year second quarter Increases 2023
Aurinia Pharmaceuticals reported strong financial results for the second quarter of 2023, with a net revenue of $41.5 million, marking a 47% increase compared to the previous year. The company raised its revenue guidance for the year to a range of $150 to $160 million, reflecting positive commercial performance of its product LUPKYNIS. Additionally, clinical studies have affirmed the drug's efficacy in treating lupus nephritis. However, the company continues to face high operational costs.
Read more →AUPHAURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATIONAL RESULTS $34.4 million in net revenue for the first quarter of 2023 an increase of 59% over the first quarter of the prior year Increases 2023 r
Aurinia Pharmaceuticals reported a significant increase in net revenue for Q1 2023, reaching $34.4 million, a 59% rise compared to the same period last year. The company has boosted its revenue guidance for 2023, anticipating sales of $135 to $155 million, driven by the performance of its drug LUPKYNIS. Additionally, strong patient metrics show consistent conversion rates and improved patient persistency on therapy. However, the company reported a net loss of $26.2 million for the quarter, though this represents an improvement from the previous year’s losses.
Read more →AUPHAurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial LUPKYNIS treated patients showed histologic activity improvement with stable chronicity scores similar to active co
Aurinia Pharmaceuticals announced promising results from the AURORA Trial's Renal Biopsy Sub-Study, indicating that LUPKYNIS-treated patients showed significant histologic activity improvement while maintaining stable chronicity scores. The findings suggest LUPKYNIS's effectiveness is on par with the current standard of care, while highlighting its differentiation from first-generation calcineurin inhibitors. The company aims to share further details at the upcoming Congress of Clinical Rheumatology meeting. The results underscore the potential long-term efficacy and safety of LUPKYNIS in treating lupus nephritis.
Read more →AUPH▲ +9.1%on this news
AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND COMPANY UPDATES $28.4 million in total net revenue for the fourth quarter 2022, a 21% increase over fourth quarter 2021 and $134.0 million for full
Aurinia Pharmaceuticals reported strong financial results for Q4 and full year 2022, with total net revenue reaching $28.4 million in the quarter and $134.0 million for the year, marking a significant year-over-year increase of 194%. The company continues to improve patient outreach for its product LUPKYNIS, evidenced by a rising number of patients on therapy and improved conversion rates. However, Aurinia still faces challenges with net losses and a decrease in newly added PSFs in the recent quarter. The company reaffirms its revenue guidance for the fiscal year 2023, signaling confidence in ongoing sales growth.
Read more →AUPHAURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS Net revenue of $55.8 million for Q3 2022 including $30.0 million milestone from Otsuka related to European Approval of LUPKYNIS (voclos
AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS Net revenue of $55.8 million for Q3 2022 including $30.0 million milestone from Otsuka related to European Approval of LUPKYNIS (voclosporin) Adjusts net product revenue guidance to $100-105 mi
Read more →AUPHAURINIA REPORTS SECOND QUARTER AND SIX MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS Net revenue increased to $28.2 million for Q2 2022 Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS (vo
AURINIA REPORTS SECOND QUARTER AND SIX MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS Net revenue increased to $28.2 million for Q2 2022 Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS (voclosporin) for 2022 Continued increases in LUPKYNIS Patien
Read more →AUPH▼ -13.3%on this news
Aurinia Pharmaceuticals Investors: Class Action Lawsuit Filed on Behalf of Investors; The Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 13, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ("Aurinia" or the "Company") investors that a class action filed on
Read more →AUPHAurinia Pharmaceuticals Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 02, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ("Aurinia" or the "Company") investors that a class action filed on b
Read more →AUPH▲ +26%on this newsshared move
AURINIA REPORTS FIRST QUARTER 2022 FINANCIAL AND OPERATIONAL RESULTS $21.6 million in net revenue for Q1 2022 Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS for 2022 Continued increases
AURINIA REPORTS FIRST QUARTER 2022 FINANCIAL AND OPERATIONAL RESULTS $21.6 million in net revenue for Q1 2022 Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS for 2022 Continued increases in LUPKYNIS (voclosporin) Patients on Treatment and Patien
Read more →AUPHAurinia Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Lawsuit Against Aurinia Pharmaceuticals Inc. (AUPH)
SAN DIEGO, April 22, 2022 (GLOBE NEWSWIRE) -- The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securi
Read more →AUPH▼ -24.3%on this news
AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND COMPANY UPDATES $23.4 million in net revenue for the fourth quarter 2021 (60% increase from third quarter) and $45.6 million in net revenue for full
AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND COMPANY UPDATES $23.4 million in net revenue for the fourth quarter 2021 (60% increase from third quarter) and $45.6 million in net revenue for full year 2021 2021 readout of strong results from AURORA 2 co
Read more →AUPH▼ -5%on this news
AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2021 FINANCIAL RESULTS AND COMPANY UPDATES $14.7 million in net revenue for the third quarter 2021 (122% increase from second quarter 2021) Steady increases in LUPKYNIS Patie
AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2021 FINANCIAL RESULTS AND COMPANY UPDATES $14.7 million in net revenue for the third quarter 2021 (122% increase from second quarter 2021) Steady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage Addit
Read more →AUPHConfidential Riptide Aurinia Collaboration License Agreement Between Aurinia Pharmaceuticals Inc. and Riptide Bioscience, Inc. Effective Date
Certain identified information has been excluded from this document because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Article 1 Interpretation 1 Article 2 Grant of Rights 13 Article 3 Restrictions 17 Article 4 Joint Development Co
Read more →AUPHAURINIA REPORTS SECOND QUARTER AND SIX MONTHS 2021 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS - $6.6 million in net revenue for the second quarter 2021 (624% increase from first quarter 2021) - - 415 patient sta
AURINIA REPORTS SECOND QUARTER AND SIX MONTHS 2021 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS -$6.6 million in net revenue for the second quarter 2021 (624% increase from first quarter 2021) - -415 patient start forms (PSFs) received for LUPKYNISTM during the second qu
Read more →AUPHAurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange VICTORIA, British Columbia
Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange VICTORIA, British Columbia - July 16, 2021 - Aurinia Pharmaceuticals Inc. (NASDAQ AUPH TSX AUP) (Aurinia or the Company), a commercial stage biopharmaceutical company advancing therapies for severe autoi
Read more →AUPHAurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA) VICTORIA, British Columbia and
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA) VICTORIA, British Columbia and ROCKVILLE, Maryland - June 25, 2021 - Aurinia Pharmaceuticals Inc. (NASDAQ AUPH TSX AUP) (th
Read more →AUPHAurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors VICTORIA, British Columbia
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors VICTORIA, British Columbia - June 14, 2021 - Aurinia Pharmaceuticals Inc. (NASDAQ AUPH TSX AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to t
Read more →AUPHAURINIA REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS - Quarter highlights include FDA approval, launch and early market penetration of LUPKYNIS TM as the first approved oral therapy for
AURINIA REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS - Quarter highlights include FDA approval, launch and early market penetration of LUPKYNISTM as the first approved oral therapy for lupus nephritis (LN) - -Over 250 patient start forms receiv
Read more →AUPHAURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS - LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible ki
AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS - LUPKYNISTM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardia
Read more →AUPHItem 8 Executive Officer For further information, please contact Mr. Joseph M. Miller, Chief Financial Officer 240-291-6917 jmiller auriniapharma.com Item 9 Date of Report
Material Change Report Item 1 Name and Address of Company Aurinia Pharmaceuticals Inc. (the Company ) #1203-4464 Markham Street Victoria, BC V8Z 7X8 Item 2 Date of Material Change A news release was issued and disseminated by the Company through Business News Wire on Decemb
Read more →AUPHAurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan - Aurinia to receive $50 million U.S. upfront paym
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan - Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and
Read more →AUPHAurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity - State-of-the-Art Monoplant Will Provide Cost and Production Efficiency and Secure Active Pharmaceutical Ingredient (API) S
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity - State-of-the-Art Monoplant Will Provide Cost and Production Efficiency and Secure Active Pharmaceutical Ingredient (API) Supply for Future Commercial Demand - VICTORIA, British Col
Read more →AUPHAurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) VICTORIA, British Columbia--(BUSINESS WIRE)
Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) VICTORIA, British Columbia--(BUSINESS WIRE)--November 20, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical comp
Read more →AUPHFinancial Statements Third Quarter Ended
Financial Statements Third Quarter Ended September 30, 2020 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at September 30, 2020 (expressed in thousands of US dollars) September 30, 2020 $ December 31, 2019 $ Ass
Read more →AUPHAurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights - U.S. Food & Drug Administration grants Priority Review for voclosporin and sets PDUFA date of
Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights - U.S. Food & Drug Administration grants Priority Review for voclosporin and sets PDUFA date of January 22, 2021 - - Cash, cash equivalents and investments totaled approximately $421 million
Read more →AUPHAurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020 - Integrated analysis confirms addition of voclosporin
Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020 - Integrated analysis confirms addition of voclosporin to standard-of-care resulted in faster Renal Response comp
Read more →AUPHAurinia Announces Outcome of AUDREY Clinical Trial in Dry Eye Syndrome - The trial did not achieve statistical significance on the primary endpoint of 10mm improvement in Schirmer Tear Test (STT) at 4 weeks - - Company t
Aurinia Announces Outcome of AUDREY Clinical Trial in Dry Eye Syndrome - The trial did not achieve statistical significance on the primary endpoint of 10mm improvement in Schirmer Tear Test (STT) at 4 weeks - - Company to suspend development program for voclosporin ophthalmic s
Read more →AUPHAurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19 VICTORIA, British Columbia--(BUSINESS WIRE)
Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19 VICTORIA, British Columbia--(BUSINESS WIRE)--October 27, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or t
Read more →AUPHAurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020 - Integrated analysis confirms statistically superior efficacy and safe
Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020 - Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over
Read more →AUPHAurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com VICTORIA, British Columbia--(BUSINESS WIRE)
Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com VICTORIA, British Columbia--(BUSINESS WIRE)--October 14, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "
Read more →AUPHAurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VICTORIA, British Columbia--(BUSINESS WIRE)
Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VICTORIA, British Columbia--(BUSINESS WIRE)--October 2, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical compa
Read more →AUPHAurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome - Voclosporin ophthalmic solution (VOS) results on track to be reported in the fourth q
Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome - Voclosporin ophthalmic solution (VOS) results on track to be reported in the fourth quarter of 2020 - - Study builds on positive head-to-head d
Read more →AUPHAurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)
Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--September 4, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biop
Read more →AUPHAurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights - U.S. Food & Drug Administration grants Priority Review for voclosporin and sets PDUFA date of
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights - U.S. Food & Drug Administration grants Priority Review for voclosporin and sets PDUFA date of January 22, 2021 - - Cash, cash equivalents and short term investments totaled approximately $
Read more →AUPHFinancial Statements Second Quarter Ended
Financial Statements Second Quarter Ended June 30, 2020 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at June 30, 2020 (expressed in thousands of US dollars) June 30, 2020 $ December 31, 2019 $ Assets Current
Read more →AUPHAurinia Announces Public Offering of Common Shares VICTORIA, British Columbia--(BUSINESS WIRE)
Aurinia Announces Public Offering of Common Shares VICTORIA, British Columbia--(BUSINESS WIRE)--July 22, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in m
Read more →AUPHFORM 51-102F3 Material Change Report Item 1 Name and Address of Company Aurinia Pharmaceuticals Inc. (the Company ) #1203-4464 Markham Street Victoria, BC V8Z 7X8 Canada Item 2 Date of Material Change
Material Change Report Aurinia Pharmaceuticals Inc. (the Company ) #1203-4464 Markham Street Victoria, BC V8Z 7X8 News releases were issued and disseminated by the Company through Business News Wire on July 21, 2020. On July 21, 2020, the Company announced that the U.S. Food
Read more →AUPHAurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis - FDA grants Priority Review and sets PDUFA da
Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis - FDA grants Priority Review and sets PDUFA date of January 22, 2021 - VICTORIA, British Columbia & ROCK
Read more →AUPHAurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome - Voclosporin ophthalmic solution (VOS) results anticipated in the fo
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome - Voclosporin ophthalmic solution (VOS) results anticipated in the fourth quarter of 2020 - VICTORIA, British Columbia--(BUSINE
Read more →AUPHAurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020 VICTORIA, British Columbia--(BUSINESS WIRE)
Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020 VICTORIA, British Columbia--(BUSINESS WIRE)--June 9, 2020--Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutica
Read more →AUPHAurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress - All pre-specified subgroup analyses in the pivotal trial favored voclosporin over placebo - VICTORIA, British Columbia--(BUSINESS WIR
Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress - All pre-specified subgroup analyses in the pivotal trial favored voclosporin over placebo - VICTORIA, British Columbia--(BUSINESS WIRE)--June 5, 2020--Aurinia Pharmaceuticals Inc. (Nasdaq:AUP
Read more →AUPHAurinia Announces Results of Annual General Meeting VICTORIA, British Columbia--(BUSINESS WIRE)
Aurinia Announces Results of Annual General Meeting VICTORIA, British Columbia--(BUSINESS WIRE)--June 3, 2020--Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX: AUP) ("Aurinia" or the "Company") is pleased to announce that the nine incumbent directors of the Company were electe
Read more →AUPHAurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis - Potential for voclosporin to become the first FDA-approved therapy for th
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis - Potential for voclosporin to become the first FDA-approved therapy for the treatment of lupus nephritis - - NDA Application support
Read more →AUPHFinancial Statements First Quarter Ended
Financial Statements First Quarter Ended March 31, 2020 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at March 31, 2020 (expressed in thousands of US dollars) March 31, 2020 $ December 31, 2019 $ Assets Curre
Read more →AUPHAurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights - Cash and cash equivalents totaled approximately $286 million at
Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights - Cash and cash equivalents totaled approximately $286 million at March 31, 2020 - - Rolling submission of voclosporin New Drug Application to the U.S. Food & Drug Administration remains on t
Read more →AUPHAurinia Appoints Joe Miller as Chief Financial Officer - Dennis Bourgeault to retire after more than 20 years with the company - VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)
Aurinia Appoints Joe Miller as Chief Financial Officer - Dennis Bourgeault to retire after more than 20 years with the company - VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--April 27, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the
Read more →AUPHAurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)
Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--April 20, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutica
Read more →AUPHAurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings - Data to be shared as a late-breaking oral presentation durin
Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings - Data to be shared as a late-breaking oral presentation during the live virtual NKF conference - VICTORIA, British Colu
Read more →AUPHAurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland VICTORIA, British Columbia--(BUSINESS WIRE)
Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland VICTORIA, British Columbia--(BUSINESS WIRE)--March 17, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical c
Read more →AUPHAurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis - Company remains on track to complete submissio
Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis - Company remains on track to complete submission by the end of the second quarter 2020 - VICTORIA, Britis
Read more →AUPHAurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative - Company recognizes World Kidney Day and National Kidney Month - VICTORIA, Britis
Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative - Company recognizes World Kidney Day and National Kidney Month - VICTORIA, British Columbia--(BUSINESS WIRE)--March 12, 2020--Aurinia Pharm
Read more →AUPHAurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights - Cash and cash equivalents totaled approximately $306 million at
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights - Cash and cash equivalents totaled approximately $306 million at December 31, 2019 - - Positive AURORA Phase 3 results with voclosporin enabling an NDA submission for the treatment o
Read more →AUPHAurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team - Industry veteran, Max Colao, appointed Chief Commercial Officer - - Recruited four seasoned executives with expertise a
Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team - Industry veteran, Max Colao, appointed Chief Commercial Officer - - Recruited four seasoned executives with expertise across critical commercial functions - - Rapidly preparing
Read more →AUPHAurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters Option to Purchase Additional Common Shares VICTORIA, British Columbia (BUSINESS WIRE)
Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters Option to Purchase Additional Common Shares VICTORIA, British Columbia (BUSINESS WIRE) December 12, 2019 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ( Aurinia or the Com
Read more →AUPHAurinia Announces Public Offering of Common Shares VICTORIA, British Columbia (BUSINESS WIRE)
Aurinia Announces Public Offering of Common Shares VICTORIA, British Columbia (BUSINESS WIRE) December 9, 2019 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ( Aurinia or the Company ), a late- stage clinical biopharmaceutical company focused on advancing voclosporin in m
Read more →AUPHAurinia Prices US$166.7 Million Public Offering of Common Shares VICTORIA, British Columbia (BUSINESS WIRE)
Aurinia Prices US$166.7 Million Public Offering of Common Shares VICTORIA, British Columbia (BUSINESS WIRE) December 9, 2019 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ( Aurinia or the Company ), a late-stage clinical biopharmaceutical company focused on advancing voc
Read more →AUPHAurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis - Voclosporin achieved statistically superior Renal Response rate (p 0.001) and compa
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis - Voclosporin achieved statistically superior Renal Response rate (p < 0.001) and comparable safety profile versus standard of care - - Statist
Read more →AUPHAurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference - Voclosporin demonstrated fewer adverse effects on beta cell function as compared to tacrolimus in preclinical model of diabetes - - D
Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference - Voclosporin demonstrated fewer adverse effects on beta cell function as compared to tacrolimus in preclinical model of diabetes - - Data supports differentiation of voclosporin versus legacy
Read more →AUPHAurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights - Conference call and webcast to be hosted today at 4:30pm EDT - VICTORIA, British Columbia--(BUSINESS WIRE)
Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights - Conference call and webcast to be hosted today at 4:30pm EDT - VICTORIA, British Columbia--(BUSINESS WIRE)--November 14, 2019--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) ("Aurini
Read more →AUPHAurinia Announces Updates to the Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)
Aurinia Announces Updates to the Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)--November 13, 2019--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclospor
Read more →AUPHAurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil - Data support differentiation of voclosporin as a potential best-in-class CNI - VI
Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil - Data support differentiation of voclosporin as a potential best-in-class CNI - VICTORIA, British Columbia--(BUSINESS WIRE)--November 7, 201
Read more →AUPHAurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY Clinical Trial for Dry Eye Syndrome - Voclosporin ophthalmic solution (VOS) AUDREY trial results anticipated in the second half of 2020 - VICTORIA, Briti
Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY Clinical Trial for Dry Eye Syndrome - Voclosporin ophthalmic solution (VOS) AUDREY trial results anticipated in the second half of 2020 - VICTORIA, British Columbia--(BUSINESS WIRE)--October 31, 2019--Aurinia Ph
Read more →AUPHAurinia Reports Second Quarter 2019 Financial Results and Operational Highlights - Fully-enrolled AURORA Phase 3 trial in lupus nephritis continues on track with results anticipated in late 2019 - - Initiating AUDREY Pha
Aurinia Reports Second Quarter 2019 Financial Results and Operational Highlights - Fully-enrolled AURORA Phase 3 trial in lupus nephritis continues on track with results anticipated in late 2019 - - Initiating AUDREY Phase 2/3 clinical study for VOS in Dry Eye Syndrome - - Con
Read more →AUPHAurinia Announces Further Strengthening of the Senior Management Team - Max Donley appointed EVP, Internal Operations and Strategy - - Glenn Schulman appointed SVP, Corporate Communications and Investor Relations - VICTO
Aurinia Announces Further Strengthening of the Senior Management Team - Max Donley appointed EVP, Internal Operations and Strategy - - Glenn Schulman appointed SVP, Corporate Communications and Investor Relations - VICTORIA, British Columbia--(BUSINESS WIRE)--July 18, 2019--Au
Read more →AUPHAurinia Shareholders Elect all Eight Directors at 2019 Annual General Meeting Shareholders Overwhelmingly Support Aurinia and its Board of Directors Dissident Withdraws the Consents of its Nominees from Consideration Pri
Aurinia Shareholders Elect all Eight Directors at 2019 Annual General Meeting Shareholders Overwhelmingly Support Aurinia and its Board of Directors Dissident Withdraws the Consents of its Nominees from Consideration Prior to the AGM Aurinia Reaffirms its Commitment to Voclosp
Read more →AUPHAurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline Shareholders can vote the YELLOW proxy even if they previously voted on the green proxy Proxy voting deadline is 10:00 AM Mountain Time on M
Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline Shareholders can vote the YELLOW proxy even if they previously voted on the green proxy Proxy voting deadline is 10:00 AM Mountain Time on Monday, June 24th VICTORIA, British Columbia--(BUSINESS WI
Read more →AUPHLeading Independent Proxy Advisors Recommend Aurinia Shareholders Vote the YELLOW Proxy Card FOR All of Aurinia's Director Nominees ISS and Glass Lewis Recommend Aurinia Shareholders Not Support ILJIN's Nominees Highligh
Leading Independent Proxy Advisors Recommend Aurinia Shareholders Vote the YELLOW Proxy Card FOR All of Aurinia's Director Nominees ISS and Glass Lewis Recommend Aurinia Shareholders Not Support ILJIN's Nominees Highlight Aurinia's Strong Track Record of Shareholder Value Creat
Read more →AUPHAurinia Issues Letter to Shareholders Highlights the Company's strong progress, advancement of voclosporin, and value creation for all shareholders Notes recent Board refreshment, deep expertise in drug commercialization
Issues Letter to Shareholders the Company's strong progress, advancement of voclosporin, and value creation for all shareholders recent Board refreshment, deep expertise in drug commercialization ILJIN has offered no plan for value creation ILJIN's misrepresentations; notes
Read more →AUPHAurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders - Special Committee of the Board and Management urges you to vote your shares using the YELLOW proxy - VICTORIA, British Columbia--(BUSINE
Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders Special Committee of the Board and Management urges you to vote your shares using the YELLOW VICTORIA, British Columbia--(BUSINESS WIRE)--May 31, 2019--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AU
Read more →AUPHAurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at
Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at March 31, 2019 (expressed in thousands of US dollars) March 31, 2019 $ December 31, 2018 $ Assets Current assets Cash and cash equivalents 140,359 117,967
Read more →AUPHAurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights - Conference call and webcast to be hosted today at 4:30pm EDT - VICTORIA, British Columbia--(BUSINESS WIRE)
Reports First Quarter 2019 Financial Results and Recent Operational Conference call and webcast to be hosted today at 4:30pm EDT - VICTORIA, British Columbia--(BUSINESS WIRE)--May 14, 2019--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) ("Aurinia" or the "Company") tod
Read more →AUPHAurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis VICTORIA, British Columbia--(BUSINESS WIRE)
Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis VICTORIA, British Columbia--(BUSINESS WIRE)--May 10, 2019--In recognition of Lupus Awareness Month and World Lupus Day, Aurinia Pharmaceuticals Inc. (NASDAQ:A
Read more →AUPHAurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen VICTORIA, British Columbia--(BUSINESS WIRE)
Further Strengthens Its Board of Directors with the Appointment of Dr. VICTORIA, British Columbia--(BUSINESS WIRE)--April 30, 2019--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a clinical stage biopharmaceutical company focused on the glo
Read more →AUPHAurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board Appointments effective as of
Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman effective as of April 29, 2019 Richard M. Glickman to retire from executive and board roles and remain an advisor to the Company fo
Read more →AUPHAurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights VICTORIA, British Columbia--(BUSINESS WIRE)
Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights VICTORIA, British Columbia--(BUSINESS WIRE)--March 19, 2019--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company") today reported its financial results for the
Read more →AUPHAurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease VICTORIA, British Columbia--(BUSINESS WIRE)
Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease VICTORIA, British Columbia--(BUSINESS WIRE)--March 14, 2019--In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (N
Read more →AUPHAurinia Closes At-The-Market Facility VICTORIA, British Columbia--(BUSINESS WIRE)
Closes At-The-Market Facility VICTORIA, British Columbia--(BUSINESS WIRE)--February 27, 2019--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the "Company") today announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on Novemb
Read more →AUPHAurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis Allowed claims cover an individualized flat-dosed pharmacodyna
Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus claims cover an individualized flat-dosed pharmacodynamic treatment protocol utilized in the AURA-LV study and the ongoing AURORA study i
Read more →AUPHAurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome VOS showed statistical superiority to R
Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome showed statistical superiority to Restasis on FDA-accepted objective of VOS subjects vs 18.4% of Restas
Read more →AUPHAURINIA ESTABLISHES AT-THE-MARKET FACILITY Victoria, British Columbia
AURINIA ESTABLISHES AT-THE-MARKET FACILITY Victoria, British Columbia November 30, 2018: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ( Aurinia or the Company ) today announced that it has entered into an Open Market Sale Agreement (the Sale Agreement ) with Jefferies L
Read more →AUPHAurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development AURORA Phase III Trial in lupus nephritis completes enrollment ahead of schedule Phase II data for the treatment of dry eye e
Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development Phase III Trial in lupus nephritis completes enrollment ahead of II data for the treatment of dry eye expected in January 2019 II FSGS Trial ongoing M. Glickman announces his intention to
Read more →AUPHAurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis -Target enrollment has been exceeded and completed ahead of schedule -Company anticipates primary data analysis in Q
Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis enrollment has been exceeded and completed ahead of schedule anticipates primary data analysis in Q4 2019 VICTORIA, British Columbia--(BUSINESS WIRE)--September 25, 2018--Aurinia
Read more →AUPHAurinia Reports Second Quarter Financial Results and Operational Highlights AURORA Phase III Trial in lupus nephritis anticipated to complete enrollment ahead of schedule Trials in FSGS and Dry Eye initiated VICTORIA, Br
Reports Second Quarter Financial Results and Operational Highlights Phase III Trial in lupus nephritis anticipated to complete enrollment FSGS and Dry Eye initiated VICTORIA, British Columbia--(BUSINESS WIRE)--August 9, 2018--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AU
Read more →AUPHAurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome VICTORIA, British Columbia--(BUSINESS WIRE)
Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome VICTORIA, British Columbia--(BUSINESS WIRE)--July 11, 2018--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on t
Read more →AUPHAurinia Initiates Clinical Trials Broadening the Development of Voclosporin -First lupus nephritis patients roll over into AURORA 2 extension study -Phase II FSGS Trial Initiated VICTORIA, British Columbia--(BUSINESS WIR
Initiates Clinical Trials Broadening the Development of Voclosporin lupus nephritis patients roll over into AURORA 2 extension study II FSGS Trial Initiated VICTORIA, British Columbia--(BUSINESS WIRE)--June 25, 2018--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clini
Read more →AUPHAurinia Reports First Quarter Financial Results and Operational Highlights AURORA Phase III Trial in lupus nephritis remains on track Trials in FSGS and Dry Eye expected to begin in June 2018 VICTORIA, British Columbia--
Reports First Quarter Financial Results and Operational Highlights Phase III Trial in lupus nephritis remains on track FSGS and Dry Eye expected to begin in June 2018 VICTORIA, British Columbia--(BUSINESS WIRE)--May 10, 2018--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AU
Read more →AUPHAurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights AURORA Phase III Trial in lupus nephritis on track Trials in FSGS and Dry Eye to begin in Q2 2018 Cash of $173.5 million as o
Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights Phase III Trial in lupus nephritis on track FSGS and Dry Eye to begin in Q2 2018 $173.5 million as of December 31, 2017 VICTORIA, British Columbia--(BUSINESS WIRE)--March 15, 2018--Aurinia
Read more →AUPHAurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)
Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)--February 22, 2018--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a clini
Read more →AUPHAurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)
Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)--February 8, 2018--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a clinica
Read more →AUPHAurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus VICTORIA, British Columbia--(BUSINESS WIRE)--January 4, 2018--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company") today announced that in order
Read more →AUPHAurinia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements (Unaudited) (Expressed in thousands of United States (U.S.) dollars) Third Quarter ended
Aurinia Pharmaceuticals Inc. Consolidated Financial Statements (Expressed in thousands of United States (U.S.) dollars) Quarter ended September 30, 2017 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Expressed in thousands of U
Read more →AUPHAurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights AURORA Phase III Trial in lupus nephritis on track Trials in FSGS, MCD and Dry Eye to begin in the first half of 2018 Cash of $182.
Reports Third Quarter 2017 Financial Results and Provides Operational Phase III Trial in lupus nephritis on track FSGS, MCD and Dry Eye to begin in the first half of 2018 $182.4 million as of September 30, 2017 VICTORIA, British Columbia--(BUSINESS WIRE)--November 14, 2017--A
Read more →AUPHAurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome Company to Initiate Clinical Trials for Treatment of FSGS, MCD, and Dry Eye in 2018 with Data Re
to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome to Initiate Clinical Trials for Treatment of FSGS, MCD, and Dry Eye in 2018 with Data Readouts in Second Half of 2018 Day Featuring KOLs in Nephrology and Ophth
Read more →AUPHAurinia to Host R&D Day and Webcast on October 20 th in New York, NY Presentations will highlight strategy to expand voclosporin's opportunity in novel indications VICTORIA, British Columbia--(BUSINESS WIRE)
to Host R&D Day and Webcast on October 20th will highlight strategy to expand voclosporin's opportunity in novel VICTORIA, British Columbia--(BUSINESS WIRE)--September 19, 2017--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will host an R&D D
Read more →AUPHAurinia to Webcast at Upcoming Investor Conferences VICTORIA, British Columbia--(BUSINESS WIRE)
Aurinia to Webcast at Upcoming Investor Conferences VICTORIA, British Columbia--(BUSINESS WIRE)--September 5, 2017--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") plans to present at three upcoming investor conferences where Aurinia management
Read more →AUPHAurinia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements (Unaudited) (Expressed in thousands of United States (U.S.) dollars) Second quarter ended
Aurinia Pharmaceuticals Inc. Consolidated Financial Statements (Expressed in thousands of United States (U.S.) dollars) Second quarter ended June 30, 2017 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Expressed in thousands of
Read more →AUPHAurinia Reports Second Quarter 2017 Financial Results, and Provides Operational Highlights AURORA Phase III Trial with Voclosporin Has Been Initiated Cash of $190 million as of
Reports Second Quarter 2017 Financial Results, and Provides Operational Phase III Trial with Voclosporin Has Been Initiated $190 million as of June 30, 2017 VICTORIA, British Columbia--(BUSINESS WIRE)--August 10, 2017--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Au
Read more →AUPHAurinia Resolves Temporary Non-Compliance with Nasdaq's Audit Committee Composition Rule VICTORIA, British Columbia--(BUSINESS WIRE)
Resolves Temporary Non-Compliance with Nasdaq's Audit Committee VICTORIA, British Columbia--(BUSINESS WIRE)--July 12, 2017--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") today announced the receipt of a letter from The NASDAQ Stock Market L
Read more →AUPHVoclosporin Remission Data from the Phase IIb AURA-LV Study Highlighted at EULAR 2017 -Patients on voclosporin achieve remission faster and maintain remission longer when compared to control -Data presented during late-b
Remission Data from the Phase IIb AURA-LV Study Highlighted at EULAR 2017 on voclosporin achieve remission faster and maintain remission longer when compared to control presented during late-breaking session VICTORIA, British Columbia--(BUSINESS WIRE)--June 16, 2017--Aurinia
Read more →AUPHAurinia Presents Additional Data from Phase IIB AURA-LV Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks -Data highlight voclosporin's additional differenti
Presents Additional Data from Phase IIB AURA-LV Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks highlight voclosporin's additional differentiation from its therapeutic VICTORIA, British Columbia--(BUSINESS WIRE)
Read more →AUPHAURINIA PHARMACEUTICALS INC. Notice of Annual General Meeting of Shareholders NOTICE is hereby given that the Annual General Meeting (the Meeting ) of shareholders of Aurinia Pharmaceuticals Inc. (the Company ) will be h
AURINIA PHARMACEUTICALS INC. Notice of Annual General Meeting of Shareholders NOTICE is hereby given that the Annual General Meeting (the Meeting ) of shareholders of Aurinia Pharmaceuticals Inc. (the Company ) will be held at 1200 Waterfront Centre, 200 Burrard Street, Vancou
Read more →AUPHAurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis VICTORIA, British Columbia--(BUSINESS WIRE)
Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in VICTORIA, British Columbia--(BUSINESS WIRE)--May 17, 2017--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) ("Aurinia" or the "Company"), a clinical stage biopharmaceutical company focused on the global
Read more →AUPHFinancial statements First quarter ended march 31, 2017 Q1 17 Financial Statements First Quarter Ended
Financial statements First quarter ended march 31, 2017 Q1 17 Financial Statements First Quarter Ended March 31, 2017 Q1 17 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements (expressed in thousands of US dollars) First Quarter Ended March 31, 2
Read more →AUPHAurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights AURORA Phase III Trial with Voclosporin Has Been Initiated Cash of $202.1
Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights Phase III Trial with Voclosporin Has Been Initiated $202.1 million as of March 31, 2017, Providing Resources to Fund Company Phase IIb Tr
Read more →AUPHPharma Industry Veteran Dr. George Milne Joins Aurinia's Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)
Industry Veteran Dr. George Milne Joins Aurinia's Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)--May 9, 2017--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a clinical stage biopharmaceutical company focused on the global i
Read more →AUPHAurinia to Present at Bloom Burton & Co. Healthcare Conference VICTORIA, British Columbia--(BUSINESS WIRE)
to Present at Bloom Burton & Co. Healthcare Conference VICTORIA, British Columbia--(BUSINESS WIRE)--April 26, 2017--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its Chief Executive Officer, Richard M. Glickman, will present at the Bloom Burton & C
Read more →AUPHAurinia Releases Additional 48-Week Data from the AURA-LV Study During Late-Breaking Session at the National Kidney Foundation 2017 Spring Clinical Meetings -Continued improvements in renal and extra-renal outcomes -100%
Releases Additional 48-Week Data from the AURA-LV Study During Late-Breaking Session at the National Kidney Foundation 2017 Spring improvements in renal and extra-renal outcomes of patients in complete remission at week 24 stay in complete remission at week 48 while on low-do
Read more →AUPHAurinia Completes Licensing Deal with Merck Animal Health for Its Nanomicellar Formulation of Voclosporin for the Treatment of Canine Dry Eye Syndrome Company retains rights to all human uses Novel topical formulation ex
Completes Licensing Deal with Merck Animal Health for Its Nanomicellar Formulation of Voclosporin for the Treatment of Canine Dry Eye Syndrome retains rights to all human uses topical formulation expands indication potential for voclosporin VICTORIA, British Columbia--(BUSINE
Read more →AUPHAurinia to Host Investor Event and Webcast on April 20 th in Orlando, FL VICTORIA, British Columbia--(BUSINESS WIRE)
to Host Investor Event and Webcast on April 20th VICTORIA, British Columbia--(BUSINESS WIRE)--April 10, 2017--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX:AUP) today announced that it will host an Investor Event during the National Kidney Foundation Spring Clinical Meeti
Read more →AUPHAurinia Announces Development Plans for Voclosporin in Europe and Japan - Single Phase III trial (AURORA) to serve as basis for regulatory submissions in major markets-US, Europe, and Japan VICTORIA, British Columbia--(B
Announces Development Plans for Voclosporin in Europe and Japan Phase III trial (AURORA) to serve as basis for regulatory submissions in major markets-US, Europe, and Japan VICTORIA, British Columbia--(BUSINESS WIRE)--April 6, 2017--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH /
Read more →AUPHAurinia Highlights 48-Week Data from Open-Label AURION Study at 12 th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017) -Biomarkers of disease activity at eight weeks can pred
Highlights 48-Week Data from Open-Label AURION Study at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017) of disease activity at eight weeks can predict renal response at 24 and VICTORIA, British Columbia--(BUSINESS WIRE)--Mar
Read more →AUPHAurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Common Shares VICTORIA, British Columbia--(BUSINESS WIRE)
Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Common Shares VICTORIA, British Columbia--(BUSINESS WIRE)--March 20, 2017--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company
Read more →AUPHAurinia Announces Presentation at 12 th International Congress on SLE (LUPUS 2017) & the 7 th Asian Congress on Autoimmunity (ACA 2017) - 48-week data from open-label AURION study to be presented on
Announces Presentation at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017) 48-week data from open-label AURION study to be presented on March 27, VICTORIA, British Columbia--(BUSINESS WIRE)--March 16, 2017--Aurinia Pharmaceu
Read more →AUPHExecution Version UNDERWRITING AGREEMENT 22,300,000 Common Shares AURINIA PHARMACEUTICALS INC. (incorporated under the Business Corporations Act (Alberta))
UNDERWRITING AGREEMENT 22,300,000 Common Shares AURINIA PHARMACEUTICALS INC. (incorporated under the Business Corporations Act (Alberta)) LEERINK PARTNERS LLC CANTOR FITZGERALD & CO. Representatives of the Several Underwriters c/o Leerink Partners LLC 299 Park Avenue, 21s
Read more →AUPHAurinia Prices US$150.5 Million Public Offering of Common Shares VICTORIA, British Columbia--(BUSINESS WIRE)
Prices US$150.5 Million Public Offering of Common Shares VICTORIA, British Columbia--(BUSINESS WIRE)--March 14, 2017--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a clinical stage biopharmaceutical company focused on the global immunology
Read more →AUPHFORM 51-102F3 Material Change Report Item 1 Name and Address of Company Aurinia Pharmaceuticals Inc. (the " Company ") #1203-4464 Markham Street Victoria, BC A1 V8Z 7X8 Item 2 Date of Material Change
Material Change Report Item 1 Name and Address of Company Aurinia Pharmaceuticals Inc. (the " Company ") #1203-4464 Markham Street Victoria, BC A1 V8Z 7X8 Item 2 Date of Material Change March 13, 2017 Item 3 News Release News releases were issued and disseminated by the Com
Read more →AUPHManufacturing Collaboration and Services Agreement (the Agreement ) by and between Lonza Ltd M nchensteinerstrasse 38 CH-4002 Basel Switzerland - hereinafter Lonza - and Aurinia Pharmaceuticals Inc. 1203-4464 Markham Str
Table of Contents Manufacturing Collaboration and Services Agreement M nchensteinerstrasse 38 - hereinafter Lonza - Aurinia Pharmaceuticals Inc. 1203-4464 Markham Street Victoria BC V8Z 7X8 Canada Effective as of 22 November 2016 (the Effective Date ) Table of Contents
Read more →AUPHAurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights AURA-LV Phase IIb Study Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lup
Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights Phase IIb Study Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study AURA-LV Data to be presented in Late Breaker Presenta
Read more →AUPHAurinia Announces Acceptance of Voclosporin Late-Breaking Presentation at the National Kidney Foundation 2017 Spring Clinical Meetings AURA-LV Phase IIb 48-week data of voclosporin for the treatment of lupus nephritis to
Announces Acceptance of Voclosporin Late-Breaking Presentation at the National Kidney Foundation 2017 Spring Clinical Meetings Phase IIb 48-week data of voclosporin for the treatment of lupus nephritis to be presented on April 20, 2017 VICTORIA, British Columbia--(BUSINESS WI
Read more →AUPHAurinia to Present at Cowen and Company 37 th Annual Healthcare Conference VICTORIA, British Columbia--(BUSINESS WIRE)
to Present at Cowen and Company 37th Annual Healthcare Conference VICTORIA, British Columbia--(BUSINESS WIRE)--March 2, 2017--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its Chief Executive Officer, Richard M. Glickman, will present at the Cowen
Read more →AUPHFORM 51-102F3 MATERIAL CHANGE REPORT ITEM 1. Name and Address of Company Aurinia Pharmaceuticals Inc. (the " Company ") 1203 - 4464 Markham Street Victoria, BC V8Z 7X8 ITEM 2. Date of Material Change
MATERIAL CHANGE REPORT ITEM 1. Name and Address of Company Aurinia Pharmaceuticals Inc. (the " Company ") 1203 - 4464 Markham Street Victoria, BC V8Z 7X8 ITEM 2. Date of Material Change March 1, 2017 ITEM 3. News Release A news release relating to the material change descri
Read more →AUPHAurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study - Low dose voclosporin achieves CR rate of 49.4% at 48 weeks (p .001) - AUROR
Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study dose voclosporin achieves CR rate of 49.4% at 48 weeks (p<.001) Phase III trial with low dose voclosporin on track to commence in Q2 2017 Con
Read more →AUPHAurinia Announces Results from Japanese Phase I Ethnic Bridging Study for Voclosporin Data support continued development of voclosporin in the Japanese patient population VICTORIA, British Columbia--(BUSINESS WIRE)
Announces Results from Japanese Phase I Ethnic Bridging Study for support continued development of voclosporin in the Japanese patient VICTORIA, British Columbia--(BUSINESS WIRE)--February 14, 2017--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Com
Read more →AUPHAurinia Announces Appointment of Company Founder, Dr. Richard M. Glickman, as its New Chief Executive Officer Aspreva Founder and CEO to lead the next stage of Aurinia's development VICTORIA, British Columbia--(BUSINESS
Announces Appointment of Company Founder, Dr. Richard M. Glickman, as its New Chief Executive Officer Founder and CEO to lead the next stage of Aurinia's development VICTORIA, British Columbia--(BUSINESS WIRE)--February 6, 2017--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TS
Read more →AUPHAurinia Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Trial - Single Phase 3 Trial on track to commence in Q2 2017 VICTORIA, British Columbia--(BUSINESS WIRE)
Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Phase 3 Trial on track to commence in Q2 2017 VICTORIA, British Columbia--(BUSINESS WIRE)--January 27, 2017--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company"), a clinica
Read more →AUPHAurinia Pharmaceuticals to Participate in Upcoming Conferences - Canaccord Genuity Rare Disease Biopharma 1x1 Day on February 7 in New York City -Leerink Partners 6 th Annual Global Healthcare Conference on February 16 i
Pharmaceuticals to Participate in Upcoming Conferences Genuity Rare Disease Biopharma 1x1 Day on February 7 in New York City Annual Global Healthcare Conference on February 16 in New York City VICTORIA, British Columbia--(BUSINESS WIRE)--January 26, 2017--Aurinia Pharmaceutic
Read more →AUPHAurinia Closes US$28 Million Financing VICTORIA, British Columbia--(BUSINESS WIRE)
Closes US$28 Million Financing VICTORIA, British Columbia--(BUSINESS WIRE)--December 28, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a clinical stage biopharmaceutical company focused on the global immunology market, today announce
Read more →AUPHAurinia Announces US$25.0 Million Bought Deal Financing VICTORIA, British Columbia--(BUSINESS WIRE)
Announces US$25.0 Million Bought Deal Financing VICTORIA, British Columbia--(BUSINESS WIRE)--December 22, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a clinical stage biopharmaceutical company focused on the global immunology marke
Read more →AUPHAurinia Announces Long-Term Manufacturing Collaboration Agreement with Lonza for Clinical and Commercial Supply of Voclosporin VICTORIA, British Columbia--(BUSINESS WIRE)
Announces Long-Term Manufacturing Collaboration Agreement with Lonza for Clinical and Commercial Supply of Voclosporin VICTORIA, British Columbia--(BUSINESS WIRE)--December 19, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP) ("Aurinia" or the "Company"), a clinical
Read more →AUPHAurinia Confirms Receipt of FDA End of Phase 2 Meeting Minutes -Minutes are consistent with previously issued preliminary responses from FDA -Single Phase 3 clinical trial to be conducted with 23.7mg BID voclosporin for
Confirms Receipt of FDA End of Phase 2 Meeting Minutes are consistent with previously issued preliminary responses from FDA Phase 3 clinical trial to be conducted with 23.7mg BID voclosporin for the treatment of active lupus nephritis (LN) on track to commence in Q2 2017 VIC
Read more →AUPHAurinia Announces Appointment of Biotech Industry Leader Jeffry Randall to its Board of Directors and Audit Committee VICTORIA, British Columbia--(BUSINESS WIRE)
Announces Appointment of Biotech Industry Leader Jeffry Randall to its Board of Directors and Audit Committee VICTORIA, British Columbia--(BUSINESS WIRE)--December 12, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a clinical stage bi
Read more →AUPHAurinia Highlights Renal Function Data from Global Phase IIb AURA Study of Voclosporin for Lupus Nephritis at American Society of Nephrology Kidney Week 2016 -AURA is the first global study of active lupus nephritis to m
Highlights Renal Function Data from Global Phase IIb AURA Study of Voclosporin for Lupus Nephritis at American Society of Nephrology Kidney is the first global study of active lupus nephritis to meet primary function remains stable throughout 24-week treatment period VICTORIA
Read more →AUPHAurinia Highlights Speed of Remission from Global Phase IIb AURA Study of Voclosporin in Lupus Nephritis at 2016 American College of Rheumatology Annual Meeting Late breaking abstract showcases first global study of acti
Highlights Speed of Remission from Global Phase IIb AURA Study of Voclosporin in Lupus Nephritis at 2016 American College of Rheumatology breaking abstract showcases global study of active lupus nephritis to meet its primary endpoint, presented on November 15th VICTORIA, Bri
Read more →AUPHAurinia Pharmaceuticals to Present at Stifel 2016 Healthcare Conference VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Present at Stifel 2016 Healthcare Conference VICTORIA, British Columbia--(BUSINESS WIRE)--November 10, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its Chief Operating Officer, Michael Martin, will present a corporate over
Read more →AUPHFORM 51-102F3 Material Change Report Item 1 Name and Address of Company Aurinia Pharmaceuticals Inc. (the Company ) #1203-4464 Markham Street Victoria, BC A1 V8Z 7X8 Item 2 Date of Material Change
Item 1 Name and Address of Company Aurinia Pharmaceuticals Inc. (the Company ) #1203-4464 Markham Street Victoria, BC A1 V8Z 7X8 Item 2 Date of Material Change November 9, 2016 Item 3 News Release A news release was issued and disseminated by the Company through Busi
Read more →AUPHAurinia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements (Unaudited) (Expressed in thousands of United States (U.S.) dollars) Third quarter ended
Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements (Expressed in thousands of United States (U.S.) dollars) Third quarter ended September 30, 2016 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaud
Read more →AUPHAurinia Reports Third Quarter 2016 Financial Results and Operational Highlights AURA first global clinical trial in lupus nephritis that meets primary and all secondary endpoints AURION 24-week results support the use of
Reports Third Quarter 2016 Financial Results and Operational Highlights first global clinical trial in lupus nephritis that meets primary and all secondary endpoints 24-week results support the use of voclosporin for the treatment of completion of EOP2 meeting with FDA VICTO
Read more →AUPHAurinia Announces Plans for Single Phase III Clinical Trial for Voclosporin in the Treatment of Lupus Nephritis Following Successful Completion of End of Phase II Meeting With FDA -Voclosporin 23.7mg BID to advance into
Announces Plans for Single Phase III Clinical Trial for Voclosporin in the Treatment of Lupus Nephritis Following Successful Completion of End of Phase II Meeting With FDA 23.7mg BID to advance into double-blind placebo controlled Phase III Phase III study design consistent w
Read more →AUPHAurinia Announces Acceptance of Late-Breaking Voclosporin Abstracts for Oral Presentation at Upcoming Medical Meetings Data to be Presented at the "Late Breaking Session" at the 2016 American College of Rheumatology/Asso
Announces Acceptance of Late-Breaking Voclosporin Abstracts for Oral Presentation at Upcoming Medical Meetings to be Presented at the "Late Breaking Session" at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meetin
Read more →AUPHAurinia Pharmaceuticals to Present at the 2016 BIO Investor Forum in San Francisco on
Pharmaceuticals to Present at the 2016 BIO Investor Forum in San Francisco on October 18, 2016 VICTORIA, British Columbia--(BUSINESS WIRE)--October 11, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) today announced that its Chief Executive Officer, Charles Rowlan
Read more →AUPHAurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates over Time for Voclosporin in the Treatment of Lupus Nephritis - Complete remission rates increase to 70% in the open-label study at 24 weeks
Releases Open-Label AURION Data Demonstrating Increased Remission Rates over Time for Voclosporin in the Treatment of Lupus Nephritis Complete remission rates increase to 70% in the open-label study at 24 in remission at eight weeks remained in remission at 24 weeks presented
Read more →AUPHAurinia Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints in Its Phase IIb AURA-LV Study for Lupus Nephritis (LN) AURA-LV is the first global active LN study to meet its primary endpoi
Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints in Its Phase IIb AURA-LV Study for Lupus Nephritis (LN) is the first global active LN study to meet its primary endpoint and all of its 24-week pre-specified secondary endpoints mortality r
Read more →AUPHAurinia Pharmaceuticals to Present at the Leerink Partners Roundtable Series in New York
Pharmaceuticals to Present at the Leerink Partners Roundtable Series in New York September 28, 2016 VICTORIA, British Columbia--(BUSINESS WIRE)--September 22, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH /TSX:AUP), a clinical stage biopharmaceutical company focused on the
Read more →AUPHAurinia Pharmaceuticals to Host Lupus Nephritis (LN) Breakfast and Webcast on September 30 th in New York Announcing detailed results from the Phase 2b AURA-LV study in patients with active LN VICTORIA, British Columbia-
Pharmaceuticals to Host Lupus Nephritis (LN) Breakfast and Webcast on detailed results from the Phase 2b AURA-LV study in patients with active VICTORIA, British Columbia--(BUSINESS WIRE)--September 21, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH;TSX:AUP) today announced t
Read more →AUPHAurinia Pharmaceuticals to Present at the 2016 Rodman & Renshaw 18 th Annual Global Investment Conference VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Present at the 2016 Rodman & Renshaw 18th Global Investment Conference VICTORIA, British Columbia--(BUSINESS WIRE)--September 7, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX:AUP) today announced that its Chief Operating Officer, Michael R. Martin
Read more →AUPHCLINICAL TRIAL UPDATE AURINIA PHARMACEUTICALS ANNOUNCES VOCLOSPORIN MEETS PRIMARY ENDPOINT IN PHASE IIB AURA-LV STUDY IN LUPUS NEPHRITIS On
CLINICAL TRIAL UPDATE AURINIA PHARMACEUTICALS ANNOUNCES VOCLOSPORIN MEETS PRIMARY ENDPOINT IN PHASE IIB AURA-LV STUDY IN LUPUS NEPHRITIS On August 15, 2016 Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company"), a clinical stage biopharmaceutical company focused on the glob
Read more →AUPHAurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis Conference call and webcast at 8am ET First therapeutic agent to meet primary endpoint in a global clinic
Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase Study in Lupus Nephritis call and webcast at 8am ET therapeutic agent to meet primary endpoint in a global clinical trial for active lupus nephritis (LN) shown to have statistically significant improvement
Read more →AUPHAurinia Reports Second Quarter 2016 Financial Results and Operational Highlights Completed private placement for gross proceeds of $7.08 million AURION results support the use of voclosporin for the treatment of lupus ne
Reports Second Quarter 2016 Financial Results and Operational Highlights private placement for gross proceeds of $7.08 million results support the use of voclosporin for the treatment of lupus topline primary endpoint results imminent VICTORIA, British Columbia--(BUSINESS WIR
Read more →AUPHAurinia Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New York VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New York VICTORIA, British Columbia--(BUSINESS WIRE)--July 28, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH;TSX:AUP) today announced it will host a Lupus Nephritis expert breakfast on Thu
Read more →AUPHAurinia Announces Appointment of Head of Communications & Advocacy VICTORIA, British Columbia--(BUSINESS WIRE)
Announces Appointment of Head of Communications & Advocacy VICTORIA, British Columbia--(BUSINESS WIRE)--July 11, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a clinical stage pharmaceutical company focused on the global nephrology m
Read more →AUPHAurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN) 57% (4/7) have achieved a complete remission as measured by a urinary protein creatinine rati
Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN) have achieved a complete remission as measured by a urinary protein creatinine ratio of 0.5mg/mg, eGFR within 20% of baseline and concomitant steroid dose of
Read more →AUPHAurinia Announces Closing of US$7 Million Private Placement VICTORIA, British Columbia--(BUSINESS WIRE)
Announces Closing of US$7 Million Private Placement VICTORIA, British Columbia--(BUSINESS WIRE)--June 22, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") has completed its previously announced private placement of 3,000,000 units of the
Read more →AUPHAurinia Announces Private Placement VICTORIA, British Columbia--(BUSINESS WIRE)
Announces Private Placement VICTORIA, British Columbia--(BUSINESS WIRE)--June 15, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company") today announced that it intends to complete a private placement of units of the Company at a price of US$2
Read more →AUPHAurinia Announces Presentations at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Meeting VICTORIA, British Columbia--(BUSINESS WIRE)
Announces Presentations at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Meeting VICTORIA, British Columbia--(BUSINESS WIRE)--May 12, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP) ("Aurinia" or the "Company") announced th
Read more →AUPHAurinia Reports First Quarter 2016 Financial Results and Operational Highlights Enrollment completed in Phase 2b clinical trial with data read out in third quarter of 2016 FDA Fast Track designation granted to voclospori
Reports First Quarter 2016 Financial Results and Operational Highlights completed in Phase 2b clinical trial with data read out in third quarter Fast Track designation granted to voclosporin for lupus nephritis AURION results support the use of voclosporin as a component of m
Read more →AUPHAurinia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements (Unaudited) (Expressed in thousands of United States (U.S.) dollars) First quarter ended
Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements (Expressed in thousands of United States (U.S.) dollars) First quarter ended March 31, 2016 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited
Read more →AUPHAurinia Initiates First Clinical Study of Voclosporin for Japan Study has potential to reduce Japanese development timelines VICTORIA, British Columbia--(BUSINESS WIRE)
Initiates First Clinical Study of Voclosporin for Japan potential to reduce Japanese development timelines VICTORIA, British Columbia--(BUSINESS WIRE)--May 9, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") announced today that after co
Read more →AUPHAURINIA PHARMACEUTICALS INC. Notice of Annual General Meeting of Shareholders NOTICE is hereby given that the Annual General Meeting (the " Meeting ") of shareholders of Aurinia Pharmaceuticals Inc. (the " Company ") wil
AURINIA PHARMACEUTICALS INC. Notice of Annual General Meeting of Shareholders NOTICE is hereby given that the Annual General Meeting (the "Meeting") of shareholders of Aurinia Pharmaceuticals Inc. (the "Company") will be held at 1200 Waterfront Centre, 200 Burrard Street, Vanco
Read more →AUPHAurinia Pharmaceuticals to Present at the 2016 Bloom Burton & Co. Healthcare Investor Conference VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Present at the 2016 Bloom Burton & Co. Healthcare VICTORIA, British Columbia--(BUSINESS WIRE)--April 28, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) today announced that its Chief Operating Officer, Michael R. Martin will present a corporate
Read more →AUPHAurinia Announces Appointment of New Chief Executive Officer Appointment enhances commercial, operational and financial expertise Brings a proven track record of building shareholder value VICTORIA, British Columbia--(BU
Aurinia Announces Appointment of New Chief Executive Officer Appointment enhances commercial, operational and financial expertise a proven track record of building shareholder value VICTORIA, British Columbia--(BUSINESS WIRE)--April 11, 2016--Aurinia Pharmaceuticals Inc. (N
Read more →AUPHAurinia Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned VICTORIA, British Columbia--(BUSINESS WIRE)
Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned VICTORIA, British Columbia--(BUSINESS WIRE)--March 29, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company") has a
Read more →AUPHAurinia Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Operational Highlights VICTORIA, British Columbia--(BUSINESS WIRE)
Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Operational Highlights VICTORIA, British Columbia--(BUSINESS WIRE)--March 18, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP) ("Aurinia" or the "Company") has released its financial results for t
Read more →AUPHAurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis VICTORIA, British Columbia--(BUSINESS WIRE)
Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis VICTORIA, British Columbia--(BUSINESS WIRE)--March 2, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") announced today that the U.S. Food and Drug A
Read more →AUPHAurinia Pharmaceuticals to Present at the 36 th Annual Cowan Health Care Conference VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Present at the 36th Annual Cowan Health Care Conference VICTORIA, British Columbia--(BUSINESS WIRE)--February 29, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that its Chief Executive Officer, Stephen W. Zaruby will present
Read more →AUPHAurinia to Host Conference Call & Webcast to Review Results from the AURION Study Conference Call and Webcast with Slides, Tuesday February 16th at 4.30pm Eastern Time VICTORIA, British Columbia--(BUSINESS WIRE)
to Host Conference Call & Webcast to Review Results from the AURION Study Call and Webcast with Slides, Tuesday February 16th at 4.30pm Eastern VICTORIA, British Columbia--(BUSINESS WIRE)--February 11, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or th
Read more →AUPHAurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis 100% of Patients receiving multi-target therapy with voclosporin achieved at least a 25% reduction of proteinuria at 8 weeks
Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis of Patients receiving multi-target therapy with voclosporin achieved at least a 25% reduction of proteinuria at 8 weeks with a mean decrease of VICTORIA, British Columbia--(BUSINESS WIRE)--
Read more →AUPHAurinia Pharmaceuticals to Attend Two Upcoming Investor Conferences Source Capital Group, 2016 Disruptive Growth & Healthcare Conference 5 th Annual Leerink Global Healthcare Conference VICTORIA, British Columbia--(BUSIN
Pharmaceuticals to Attend Two Upcoming Investor Conferences Capital Group, 2016 Disruptive Growth & Healthcare Conference Annual Leerink Global Healthcare Conference VICTORIA, British Columbia--(BUSINESS WIRE)--February 4, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH / TS
Read more →AUPHAurinia Pharmaceuticals to Present at the 18 th Annual BIO CEO & Investor Conference VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference VICTORIA, British Columbia--(BUSINESS WIRE)--February 2, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH) (TSX:AUP) today announced that its Chief Operating Officer, Michael R. Martin will present a
Read more →AUPHAurinia Pharmaceuticals to Present at the Canaccord Genuity Rare Disease and Bio-Pharma One on One Day VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Present at the Canaccord Genuity Rare Disease and Bio-Pharma One on One Day VICTORIA, British Columbia--(BUSINESS WIRE)--January 29, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) today announced that its President and CEO Stephen Zaruby will a
Read more →AUPHAurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis Primary end-point analysis expected in approximately 28 weeks VICTORIA, British Columbia--(BUSINESS WIRE)
Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study end-point analysis expected in approximately 28 weeks VICTORIA, British Columbia--(BUSINESS WIRE)--January 19, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") anno
Read more →AUPHAurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned VICTORIA, British Columbia--(BUSINESS WIRE)--November 24, 2015--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH-TSX:AUP) ("Aurinia" or the
Read more →AUPHAurinia Reports Third Quarter 2015 Financial Results VICTORIA, British Columbia--(BUSINESS WIRE)
Reports Third Quarter 2015 Financial Results VICTORIA, British Columbia--(BUSINESS WIRE)--November 13, 2015--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company") has released its financial results for the third quarter ended September 30, 2015. Am
Read more →AUPHInterim Condensed Consolidated Financial Statements (unaudited) Aurinia Pharmaceuticals Inc. Q3 15 Third Quarter Ended
Consolidated Financial Statements (unaudited) Aurinia Pharmaceuticals Inc. Ended September 30, 2015 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements (Expressed in thousands of United States Third quarter ended September 30, 2015 Aurinia Phar
Read more →AUPHAurinia Pharmaceuticals to Present at the 14 th Annual BIO Investor Forum VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Present at the Annual BIO Investor Forum VICTORIA, British Columbia--(BUSINESS WIRE)--October 19, 2015--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that its Chief Operating Officer, Michael R. Martin will present a corporate ove
Read more →AUPHAurinia Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus VICTORIA, British Columbia--(BUSINESS WIRE)--September 17, 2015--Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company"), (NASDAQ:AUPH)(TSX:AUP) announces that it has filed a preliminary short form base s
Read more →AUPHAurinia Pharmaceuticals to Present at the 2015 Rodman & Renshaw 17th Annual Global Investment Conference VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Present at the 2015 Rodman & Renshaw 17th Annual Global Investment Conference VICTORIA, British Columbia--(BUSINESS WIRE)--September 2, 2015--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH; TSX:AUP) today announced that its President and Chief Executive Officer
Read more →AUPHAurinia Reports Second Quarter 2015 Financial Results VICTORIA, British Columbia--(BUSINESS WIRE)
Reports Second Quarter 2015 Financial Results VICTORIA, British Columbia--(BUSINESS WIRE)--August 11, 2015--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company") has released its financial results for the second quarter ended June 30, 2015. Amounts
Read more →AUPHInterim Condensed Consolidated Financial Statements (unaudited) (Expressed in thousands of United States (U.S.) dollars) Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements
Consolidated Financial Statements (unaudited) (Expressed in thousands of United States (U.S.) dollars) Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Expressed in thousands of U.S. dollars) June 3
Read more →AUPHAurinia Pharmaceuticals to Present at the Canaccord Genuity 35 th Annual Growth Conference VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Present at the Annual Growth Conference VICTORIA, British Columbia--(BUSINESS WIRE)--August 6, 2015--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX:AUP) today announced that its Chief Operating Officer Michael R. Martin will present a corporate overview
Read more →AUPHAurinia Pharmaceuticals to Present at the 2015 UBS Global Health Care Conference VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Present at the UBS Global Health Care Conference VICTORIA, British Columbia--(BUSINESS WIRE)--May 19, 2015--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that its Chief Executive Officer, Stephen W. Zaruby, will present a corporate
Read more →AUPHAurinia Reports First Quarter 2015 Financial Results and Restatement of 2014 Financial Statements VICTORIA, British Columbia--(BUSINESS WIRE)
Reports First Quarter 2015 Financial Results and Restatement of 2014 Financial Statements VICTORIA, British Columbia--(BUSINESS WIRE)--May 15, 2015--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP) ("Aurinia" or the "Company") has released its financial results for the fir
Read more →AUPHAurinia Pharmaceuticals to Host Lupus Nephritis Opinion Leader Meeting and Webcast on May 5 in New York VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Host Lupus Nephritis Opinion Leader Meeting Webcast on May 5 in New York VICTORIA, British Columbia--(BUSINESS WIRE)--April 23, 2015--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP) today announced it will host a Lupus Key Opinion Leader breakfast on Tu
Read more →AUPHAurinia Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Initiation of Its Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers VICTORIA, British Colu
Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Initiation of Its Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers VICTORIA, British Columbia--(BUSINESS WIRE)--March 30, 2015--Aurinia Pharmaceuticals I
Read more →AUPHAurinia Announces Change to Its Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)
Announces Change to Its Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)--March 6, 2015--Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ:AUPH / TSX:AUP) today announced that Mr. Kurt von Emster has tendered his resignation as a member of the Au
Read more →AUPHAurinia Pharmaceuticals to Present at Cowen and Company 35 th Annual Health Care Conference VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference VICTORIA, British Columbia--(BUSINESS WIRE)--February 26, 2015--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) today announced that its Chief Executive Officer Mr. Stephen Zaruby will pr
Read more →AUPHAurinia Pharmaceuticals to Initiate an Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Initiate an Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers VICTORIA, British Columbia--(BUSINESS WIRE)--February 9, 2015--Aurinia Pharmaceuticals Inc. (the "Company") (NASDAQ:AUPH) (TSX:AUP) today announced
Read more →AUPHAurinia Pharmaceuticals Announces Recently Granted Nanomicellar Formulation Patents in Japan and China for Topical Ophthalmic Administration of voclosporin VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals Announces Recently Granted Nanomicellar Formulation Patents in Japan and China for Topical Ophthalmic Administration of VICTORIA, British Columbia--(BUSINESS WIRE)--February 3, 2015--Aurinia Pharmaceuticals Inc. (the "Company") (NASDAQ:AUPH / TSX:AUP) today an
Read more →AUPHAurinia Pharmaceuticals to Present at the BIO CEO Investor Conference VICTORIA, British Columbia--(BUSINESS WIRE)
Pharmaceuticals to Present at the BIO CEO Investor Conference VICTORIA, British Columbia--(BUSINESS WIRE)--January 29, 2015--Aurinia Pharmaceuticals, Inc., (NASDAQ: AUPH / TSX: AUP) today announced that its President and Chief Executive Officer Stephen Zaruby will present a c
Read more →AUPHAURINIA REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS Victoria, British Columbia
AURINIA REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS Victoria, British Columbia November 12, 2014: Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) has released its financial results for the third quarter ended September 30, 2014. All financial numbers are presented in U.S
Read more →AUPHAurinia Reports Third Quarter 2014 Financial Results
VICTORIA, British Columbia, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH) (TSX:AUP) has released its financial results for the third quarter ended September 30, 2014. All financial numbers are presented in U.S. dollars. Selected Third Quarter 2014
Read more →AUPHAurinia Pharmaceuticals to Host Lupus Opinion Leader Meeting and Webcast on October 23 in New York City Victoria, British Columbia
Aurinia Pharmaceuticals to Host Lupus Opinion Leader Meeting and Webcast on October 23 in New York Victoria, British Columbia October 21, 2014 Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH, Toronto Stock Exchange: AUP) today announced that it will host a Lupus Key Opinion Leader b
Read more →AUPHAurinia Pharmaceuticals to begin trading on the NASDAQ Global Market VICTORIA, BRITISH COLUMBIA September 2 nd , 2014 Aurinia Pharmaceuticals Inc. (the Company ) (TSX: AUP) today announced that the Company h
Aurinia Pharmaceuticals to begin trading on the NASDAQ Global Market VICTORIA, BRITISH COLUMBIA September 2nd, 2014 Aurinia Pharmaceuticals Inc. (the Company ) (TSX: AUP) today announced that the Company has received approval by the NASDAQ Listing Qualifications Department to l
Read more →AUPHAurinia Pharmaceuticals to Begin Trading on the NASDAQ Global Market
VICTORIA, B.C., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (the "Company") (Nasdaq:AUPH) (TSX:AUP) today announced that the Company has received approval by the NASDAQ Listing Qualifications Department to list its common shares on the NASDAQ Global Market ("NA
Read more →AUPHAurinia Pharmaceuticals Inc. NEWS RELEASE AURINIA REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS Initiates Phase 2b clinical trial of voclosporin for treatment of lupus nephritis Victoria, British Columbia
Aurinia Pharmaceuticals Inc. AURINIA REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS Initiates Phase 2b clinical trial of voclosporin for treatment of lupus nephritis Victoria, British Columbia August 14, 2014: Aurinia Pharmaceuticals Inc. (TSX: AUP) has released its financial r
Read more →AUPHAurinia Reports Second Quarter 2014 Financial Results
VICTORIA, British Columbia, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX:AUP) has released its financial results for the second quarter and six months ended June 30, 2014. All financial numbers are presented in U.S. dollars. On June 26, 2014 the Company an
Read more →AUPHAurinia Pharmaceuticals to Present at the Canaccord Genuity 34th Annual Growth Conference
VICTORIA, British Columbia, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals, Inc., (TSX:AUP) today announced that its Chief Operating Officer Michael R. Martin will present a corporate overview of the company at the Canaccord Genuity 34th Annual Growth Conference, takin
Read more →AUPHAurinia Adds Financial Expertise To Its Board Of Directors Victoria, BC July 29 th , 2014: Aurinia Pharmaceuticals Inc. ( Aurinia or the Company ) (TSX:AUP) today announced that Mr. Charles Rowland Jr. has j
Aurinia Adds Financial Expertise To Its Board Of Directors Victoria, BC July 29th, 2014: Aurinia Pharmaceuticals Inc. ( Aurinia or the Company ) (TSX:AUP) today announced that Mr. Charles Rowland Jr. has joined its Board of Directors and will assume the role of Audit Committee
Read more →AUPHAurinia Adds Financial Expertise to Its Board of Directors
VICTORIA, British Columbia, July 29, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (TSX:AUP) today announced that Mr. Charles Rowland Jr. has joined its Board of Directors and will assume the role of Audit Committee Chair. Mr. Rowland has over
Read more →AUPHAurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus Nephritis 258-Patient, Multinational, Randomized, Double-Blind, Placebo-Controlled AURA Study to Evaluate Voclosporin a
Aurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus Nephritis 258-Patient, Multinational, Randomized, Double-Blind, Placebo-Controlled AURA Study to Evaluate Voclosporin as Part of a Multi-Targeted VICTORIA, BRITISH COLUMBIA June 26, 2014 Aur
Read more →AUPHAurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus Nephritis
VICTORIA, British Columbia, June 26, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals, Inc., (TSX-V:AUP) today announced enrollment of the first patient in its planned Phase 2b clinical trial to evaluate the efficacy of voclosporin as a treatment for lupus nephritis (LN). LN is a
Read more →AUPHAurinia to Present at the BIO International Convention VICTORIA
Aurinia to Present at the BIO International Convention VICTORIA, BRITISH COLUMBIA June 23, 2014 Aurinia Pharmaceuticals, Inc., (TSX: AUP) today announced that its Chief Operating Officer, Michael R. Martin, will present a corporate overview of the company at the 2014 BIO Intern
Read more →AUPHAurinia to Present at the BIO International Convention
VICTORIA, British Columbia, June 23, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals, Inc., (TSX:AUP) today announced that its Chief Operating Officer, Michael R. Martin, will present a corporate overview of the company at the 2014 BIO International Convention as part of the bus
Read more →AUPHAurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference
VICTORIA, British Columbia, June 18, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals, Inc., (TSX:AUP) today announced that its President and Chief Executive Officer, Stephen Zaruby, will present a corporate overview of the company at the Bloom Burton & Co. Healthcare Investor Co
Read more →AUPHAurinia to Commence Trading on Toronto Stock Exchange
VICTORIA, British Columbia, June 11, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (TSX-V:AUP) today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) at the opening of the TSX on June 16th, 2014. The C
Read more →AUPHAurinia to Present at the Jefferies 2014 Global Healthcare Conference
VICTORIA, British Columbia, June 2, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals, Inc., (TSX-V:AUP) today announced that its President and Chief Executive Officer, Stephen Zaruby, will present a corporate overview of the company at the Jefferies 2014 Global Healthcare Confere
Read more →AUPHAurinia Reports First Quarter 2014 Financial Results
VICTORIA, British Columbia, May 15, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") has released its financial results for the first quarter ended March 31, 2014. On February 14, 2014, Aurinia announced that it had completed a US$52
Read more →AUPHAurinia Reports Fourth Quarter and Full Year 2013 Financial Results
VICTORIA, British Columbia, March 31, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") has released its financial results for the fourth quarter and year ended December 31, 2013. On February 14, 2014, Aurinia announced that it had co
Read more →AUPHAurinia to Present at the 26th Annual ROTH Conference
VICTORIA, British Columbia, March 4, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced that its President and CEO, Stephen Zaruby, will present an overview of the Company at the 26th Annual ROTH Conference on Monday, Ma
Read more →AUPHAurinia to Present at the 34th Annual Cowen Health Care Conference
VICTORIA, British Columbia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced that Stephen Zaruby, its President and CEO, will present an overview of the Company and an update on the development of its lead dru
Read more →AUPHAurinia Announces Management Change and Grant of Stock Options
VICTORIA, British Columbia, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced that Dr. Robert Foster has decided to resign from his current position as Chief Scientific Officer, effective immediately, in order
Read more →AUPHAurinia Announces US$52 Million Private Placement
VICTORIA, British Columbia, Feb. 14, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced that it has completed, subject to regulatory approval, a US$52 million private placement (the "Offering"). Aurinia intends to use th
Read more →AUPHAurinia Announces Change to Board of Directors
VICTORIA, B.C., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced the resignation of Dr. Robert Foster from its Board of Directors. Dr. Foster remains Chief Scientific Officer of the Company. Dr. Foster said, "
Read more →AUPHAurinia Reports Third Quarter 2013 Financial Results
VICTORIA, British Columbia, Nov. 21, 2013 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (TSX-V:AUP) has released its financial results for the third quarter ended September 30, 2013. On September 23, 2013, Aurinia announced that it had completed t
Read more →AUPHAurinia Appoints Accomplished Biotech and Pharma Industry Veteran, Stephen W. Zaruby, as President & CEO
VICTORIA, British Columbia, Nov. 6, 2013 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced the appointment of Stephen W. Zaruby as the Company's President and Chief Executive Officer. Mr. Zaruby has an accomplished history
Read more →AUPHAurinia Announces Official Name, Trading Symbol Change and Implementation of Share Consolidation
VICTORIA, British Columbia, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX-V:ISA) (the "Company") announced that, further to its press release of September 30, 2013, it has officially changed its name to Aurinia Pharmaceuticals Inc. ("Aurnia") and that its common
Read more →AUPHAurinia Pharmaceuticals Announces Post-Merger Leadership Changes and Strategic Restructuring
VICTORIA, British Columbia, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc., now operating as Aurinia Pharmaceuticals Inc. (TSX-V:ISA) ("Aurinia" or the "Company"), announced today a strategic restructuring, including senior management changes and staff reductions, desi
Read more →Competitive Position
How AUPH ranks across every disease it competes inCompetitive Position is a premium feature
See how AUPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial